Integrin Antagonists 27 Size:Contact [email protected] for quotation CH4O3S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2

CH4O3S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2

It also acts as a potent orally active insulin sensitizing agent

31)4)58-43-40(37(54)34(51)30(17-48)62-43)63-42-39(56)36(53)33(50)29(16-47)61-42/h19

Smiles: C[C@@H]1O[C@@H](O[C@H]2[C@H](OC(=O)/C=C/C3=CC(O)=C(O)C=C3)[C@@H](CO[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)O[C@@H](OCCC3C=C(O)C(O)=CC=3)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O

BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM)

Integrin Antagonists 27 Size:Contact [email protected] for quotation CH4O3S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2Integrin Antagonists 27 is a small molecule integrin v3 antagonist with binding affinity of 18 nM, as s novel anticancer agent. Target: Integrinin vitro: Integrin Antagonists 27 is treated with a panel of cancer cell lines (breast cancer cell line MDA MB 435, breast cancer cell lines MCF 7, mouse fibroblast NIH3T3, ovarian cancer cell line HEY, lung cancer cell line NCI H1975) with all IC50 of >20 uM. Product information CAS Number: 593274 97 6